P/E Ratio

The P/E ratio (price-to-earnings) of 24.7x means that investors are willing to pay $24.70 for every $1 of Amgen’s annual earnings, a standard measure of how expensive the stock is relative to its profit.

Compared to its healthcare sector, Amgen trades below the sector median of 28.3x, placing it in the 31st percentile among its peers — indicating it is cheaper than most companies in the industry. The metric has been completely flat, with a year-over-year change of +0.0% and a quarter-over-quarter change of +0.0%, reflecting a stable trend over the last eight quarters where every value was exactly 24.7x. A stable P/E below the sector median suggests a lower valuation risk compared to peers, but the lack of movement offers no clear catalyst for upward re-rating. This combination — a discounted valuation with no momentum — supports the overall NEUTRAL verdict, as the stock is neither overpriced nor showing signs of improving sentiment.

Frequently Asked Questions

Closest Sector Peers